Showing posts with label Newswire. Show all posts
Showing posts with label Newswire. Show all posts

Saturday, 20 November 2010

Gynecological onkologian Associates Dr. raminin Mirhashemi, MD handles ...-PR Newswire (press release)

Click to view news release full screen

TORRANCE, Calif., Sept 28/PRNewswire/--rotissa poor affects more than 30% of American women. However, many of the exhibition, the symptoms and do not therefore need the fibroid treatment. Treatment is only required for the poor, rotissa if the poor are large enough to cause the pressure applied to the other bodies (such as the Bladder), is growing rapidly, the cause of abnormal bleeding or cause problems with fertility. The symptoms are usually poor Rotissa heavy or abnormal bleeding and discomfort, but most women's biggest concern is the difficulty in conceiving a baby.




>
>


Dr. raminin Mirhashemi, Gynecological onkologian Associates "minimally invasive fibroid surgery improved rotissa poor, fewer problems and a faster recovery," says. "With the technology and automatic hysterectomy will improve only by way of derogation from the procedure."Da Vinci robotic surgery on the surgeon makes a small bodies in accordance with the procedure laid down in insert tools and monitor the application of a small camera, which is the subject of a patient.


It is important to keep the poor from the fertility and the design and implantation of the embryo of the wall and to facilitate the full rotissa validity, healthy pregnancy. Hysterectomy is a popular rotissa fibroid treatment, but it also removes the ability of the child, a woman maaseutuyhteisöjä. Traditional open surgery can also affect fertility scar tissue, which is based on the uterus Spiegelin from it.


There is also other less invasive treatments, which are maksafibroosin fewer characters for the patient, but still cannot keep fertility.Dr. Mirhashemi, which has the most experience in the Western United States gynecologic conditions for increased use of automatic surgery "simply put, uterus cannot be sewn back together sufficiently well to ensure healthy full-term pregnancy," said He and his staff. [1] [2] Gynecological Associates to provide comprehensive care onkologian, skills and individual attention to each patient seeking optimal gynecological care.


Thanks to the automatic use of surgeons surgery smaller tools for greater accuracy, and various of its own motion.Dr. Mirhashemi as surgeons is located close to the patient through the console inside of the monitor and control the identification of controls, and foot pedals, the robot is the camera gives a surgeon. [1] [2] in the 3D view with up to 15 X magnification. "The robot helps me See a very small blood vessels and nerves, which may spare parts, which may give rise to very little damage to surrounding tissues, "said Mirhashemi.


Dr. Mirhashemi offers these useful tips rotissa poor:

Always call your doctor If heavy bleeding, pain or forest issues. Fibroids are typically benign consists of fibrous tissues and can be found in the proper muscle. in General, Fibroids, udder rotissa wall of the uterus or outside of the poor are generally more prevalent. [3] [4] women their richest. they grow more than one tumor, or Uterine size varies according to the clusters of the poor. [1] [2] are the most common type of pelvic tumours seen gynecologists.

"When the automatic surgery popularity grows and gains acceptance, women may be the most dangerous with safer, high-performance computing (HPC) with the removal of fibroid ensures greater opportunity to preserve fertility," said Dr. Mirhashemi.


www.gynla.com


SOURCE www.gynla.com

Back to the beginning of the

RELATED LINKS
http://www.gynla.com


View the original article here

Wednesday, 17 November 2010

Stop the Medical receives Canadian License Fibroid treatment Device-PR Newswire (press release)

LIVERMORE, Calif., October 18/PRNewswire/--after Medical, Inc. announced today that it has been approved in Canada for Tulip ™ sentyyppisestä flask Thermal ablation (RFVTA)-the placing on the market of the probe. "We've just received Health Canada license for puts us closer to our goal, is an important step in making available to the women in North America, which suffer from poor millions of our rotissa rotissa sparing procedure," said Russ, President and CEO of DeLonzor, stop the Medical.   "Approvals in Canada and you have now received the European Union and for general use, as well as our recent rotissa poor to the global market for use in dentistry (is not separately reported poor) Administration in the United States, our products, THE FDA is us very well placed in the brokering activities to bring our solutions for most of the major global markets in the near future," said DeLonzor.




>
>


Information about the audit of the Medical, Inc.  


Stop the Medical, Inc. is a medical device which forms part of a planning and close to San Francisco, CA the manufacture of products from developing countries, the company for the next generation of RFVTA ablate tissues with the system.Audit of the system for general use, THE FDA has been cleared and is currently in the United States and Latin America, the relief shall continue to be problems caused by poor rotissa. Stop prepares commercialised stop Fibroid System on the market, if it has already been approved for general surgical and fibroid indications outside the United States, the global business opportunity to stop the. Fibroid System more than $ 2billion is estimated to be on an annual basis.


For information about how to stop the fibroid, clinical research and a list of strings, numbers, in the United States at www.clinicaltrials.gov NCT00874029 research.


SOURCE after Medical, Inc.

Back to the beginning of the

RELATED LINKS
http://www.haltmedical.com


View the original article here

Friday, 22 October 2010

InSightec: start the ExAblate - Fibroid etc Story

TIRAT CARMEL, Israel, 29 September 2010/PRNewswire/--InSightec Oy, the world's leading guided Mr Ultrasound technology (MRgFUS) announced today that it will be launching the ExAblate (R) one rotissa poor, women's health and ExAblate (R) or a system operating in the room the meeting future Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010 future adenomyosis and research settings.

ExAblate (R) family systems employs the Ultrasound non invasively

>
>
heat and destroy the targeted tissue MR control. MRI-the most advanced imaging modality system available today, identify and objectives of the tumours, but in real time temperature monitoring of the treated tissue.


Experience substances of more than 6000 patients over 80 work centers around the world ExAblate family systems offers the proven commercially approved treatments and mature forum and clinical data on a wide variety of research settings.


Innovative ExAblate (R) one to extend the treatment choices for women suffering from rotissa poor and adenomyosis.Recent ExAblate (R) technical progress now large and vascular poor and adenomyosis, expanding patient base. The ability to handle larger volumes are expected to lead to greater fibroid clinical efficacy. ExAblate (R) significantly improve adenomyosis signs, and in many cases, improve the patient's ability to overcome infertility caused by the condition.


Patients on mature rotissa poor or generally return to their normal routine adenomyosis procedure a major improvement over most fibroid treatment techniques within 24 hours. the growing number of Women has become pregnant after exposure ExAblate. studies have shown that can even improve the MRgFUS suffering from infertility caused by rotissa poor fertility. (1)


Places around the world experience has shown that the ExAblate MRgFUS increase significantly in the interest of the patient handling and transport of the port facility.Tokyo, Japan's leading site reported that the number of patients treated rotissa poor increased by 550%.(2)


ExAblate treatment has also proven cost-efficient as an alternative to the current treatments, meeting the criteria for acceptable value fibroid treatment.(3)


"MR guided relating to the use of Ultrasound (MRgFUS) has been in the treatment of the poor rotissa approved and viable option in order to increase the number of women for several years. However, the ExAblate (R) with one of the improvements offered by we can provide a more effective, more women to women's health forum is liable for imminent damage which is a fixed result for treatment alternative. "Said the head of the Professor Wladyslaw M Gedroyc, MD, radiology, St. Mary's Hospital, London, United Kingdom. " The maintenance of patients, such as the uterus and the better chance of fertility in addition to the benefits we have seen a significant reduction in the handling of the case. "


ExAblate (R) or the environment is non-invasive image Guided and Controlled Acoustic Operating System will be repeated for each room. convertible cribs with one common shown in the table below.ExAblate (R), or offer commercially accepted and research processing settings across a wide range of clinical data, such as: rotissa poor and adenomyosis, breast cancer, prostate cancer, pain palliation of bone metastases, and other characters.


One of the ExAblate (r) and the ExAblate (R) or compatible with GE Healthcare Signa and product Discovery MRI lines and has just designed ergonomic benefit patients bed, a streamlined interface, and improved usability of doctors.


"Our vision is dedicated to the ExAblate system that offers a truly non-invasive treatment, extended selection and is addressed to the safety profile. ExAblate (R) 2000 in 2004, after the introduction of market researchers, clinical and must continue to further improve and enhance innovation and accumulating compensated clinical information and knowledge," said Dr. Kobi Vortman, President and CEO, InSightec. "We control system based on the Mr Ultrasound technology only provider to offer such good and mature picture Wizard and ambient acoustic surgery".


New ExAblate (R) 1 and ExAblate (R) or patients ' bed featured InSightec booth # 44 CIRSE (2-6, October 2010, Valencia, Spain) is also hosting at. InSightec Satellite symposium, CIRSE October 3rd at the address where the senior researchers will discuss their work in the different areas of ExAblate system.For more information about InSightec is intended to serve CIRSE please visit: http://www.insightec.com


1 Rabinovici J, M, H, K, Gostout BS, Stewart EA Morita Fukunishi MRgFUS Study Group David.The results of Magnetic Resonance-guided Pregnancy active Ultrasound Surgery (MRgFUS) for the conservative treatment of the poor, fertility & rotissa sterility, 2008.


2 Yutaka Nakamura Tetsuya Morita (R) the imposition of ExAblate 2000 Add income OB/GYN Department year InSightec clinical report vol. 2, no 1


3 O'Sullivan AK, Thompson (d), Chu P, Lee DW Stewart EA Weinstein MC. cost-effectiveness of Magnetic Resonance guided ultrasound treatment as well as the poor, health rotissa, 2009 in Technology Assessment J Int. 25: 14-25


About ExAblate (R)


ExAblate (R) one and must be constructed in such a way as to improvements to research, development and dedication to InSightec has unparalleled experience and innovation with the clinical examination doctors around the world.


ExAblate ® 2000 received the CE marking in 2002 and 2004 rotissa poor treatment of the Food and Drug Administration (FDA) approval system received in June 2007, bone metastases pain palliation and adenomyosis June 2010 the European CE marking. ExAblate 2000 has won numerous innovation awards and has been used to treat thousands of patients from around the world.


About InSightec


InSightec Ltd. is a privately held company owned by Elbit Imaging, General Electric, MediTech advisors, LLC and employees., it was created in 1999 to develop breakthrough technological MR controls access to the Ultrasound and convert the next generation of operating systems in the room. Haifa, Israel, close to the Head Office of the company has more than 160 employees and has invested in more than 130 million euro to research, development and clinical trials. United States seat Dallas, Texas. [1] [2] for more information, go to: http://www.insightec.com/


Note to editors:


ExAblate (R) One received the CE marking for management of June 2010, adenomyosis. It has been approved by the FDA.

Media contact: for more information, please contact: Dr. Jane Waggener Edstrom Brearley World Tower House 10 Southampton Street Pancras London WC2E 7HA Email: jbrearley@waggeneredstrom.com phone: + 44 (0) 20 7632-3800

SOURCE InSightec Ltd

Back to the beginning of the

View the original article here